EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma

Jelena Jelicic, Karen Juul-Jensen, Zoran Bukumiric, Mikkel Runason Simonsen, Michael Roost Clausen, Ahmed Ludvigsen Al-Mashhadi, Robert Schou Pedersen, Christian Bjørn Poulsen, Anne Ortved Gang, Peter Brown, Tarec Christoffer El-Galaly, Thomas Stauffer Larsen

Clinical Lymphoma Myeloma and Leukemia · 2026

DOI: 10.1016/j.clml.2025.08.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2026. Verfasst von Jelena Jelicic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Odense University Hospital, Odense, Denmark. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Patient Selection. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The International prognostic index (IPI) is a widely used model for identifying trial-eligible patients with diffuse large B-cell lymphoma (DLBCL). However, the applicability of prognostic models in identifying trial-eligible high-intermediate (HI) and high-risk (H), particularly younger patients, has not been extensively studied. METHODS: Patients with newly diagnosed DLBCL were identified in the Danish Lymphoma Registry (LYFO). To evaluate the impact of IPI and age-adjusted IPI (aaIPI) on identifying higher-risk (HI and H-risk) trial-eligible patients, we retrieved the eligibility criteria for the frontMIND trial (NCT04824092). RESULTS: Of 6252 patients with DLBCL registered in the LYFO, 3725 (59.6%) were trial-eligible. The dataset included all IPI/aaIPI groups. However, 46% of 3725 patients would meet trial eligibility if IPI and aaIPI higher-risk patients were selected. The 5-year progression-free (PFS) and overall survival (OS) were 61.7% and 70.5%, respectively. Among patients aged ≤ 60 years (35.5%; 1321/3725), 29.5% were frontMIND-eligible based on aaIPI, with 5-year PFS and OS of 72.3% and 82.8%, respectively. Combining IPI and aaIPI did not improve the identification of patients who did not respond to standard treatment, and utilizing this strategy for trial selection was not superior to using IPI or NCCN-IPI alone. CONCLUSIONS: Prognostic models can help in selecting trial-eligible HI and H-risk patients, thereby increasing the chances of identifying those who do not respond to standard treatment. However, the currently used prognostic indices fail to accurately recognize some high-risk patients, particularly young patients. Therefore, additional risk factors beyond prognostic models are needed to improve patient selection for trial participation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffusePatient SelectionAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultPrognosisRegistriesRisk AssessmentClinical Trials, Phase III as TopicRandomized Controlled Trials as TopicMulticenter Studies as Topic

Stichwörter der Autor:innen

Clinical trialDiffuse large B cell lymphomaPrognostic modelsSelection criteriaYounger patients

Autor:innen und Institutionen

  • Department of Hematology, Odense University Hospital, Odense, Denmark.
  • Institute for Medical Statistics and Informatics, University of Belgrade, Faculty of Medicine, Belgrade, Serbia.
  • Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Mathematical Sciences, Aalborg University, Aalborg, Denmark.
  • Department of Hematology, Vejle Hospital, Sygehus Lillebaelt, Vejle, Denmark.
  • Department of Hematology, Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Hematology, Regional Hospital Gødstrup, Herning, Denmark.

Zitieren

APA

Jelicic, J., Juul-Jensen, K., Bukumiric, Z., Runason Simonsen, M., Roost Clausen, M., Ludvigsen Al-Mashhadi, A., Schou Pedersen, R., Poulsen, C. B., Gang, A. O., Brown, P., El-Galaly, T. C., & Stauffer Larsen, T. (2026). International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2025.08.020

Vancouver

Jelicic J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, Roost Clausen M, Ludvigsen Al-Mashhadi A, et al. International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2026. doi:10.1016/j.clml.2025.08.020

BibTeX
@article{Jelicic2026,
  author = {Jelicic, Jelena and Juul-Jensen, Karen and Bukumiric, Zoran and Runason Simonsen, Mikkel and Roost Clausen, Michael and Ludvigsen Al-Mashhadi, Ahmed and Schou Pedersen, Robert and Poulsen, Christian Bjørn and Gang, Anne Ortved and Brown, Peter and El-Galaly, Tarec Christoffer and Stauffer Larsen, Thomas},
  title = {International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma},
  journal = {Clinical Lymphoma Myeloma and Leukemia},
  year = {2026},
  doi = {10.1016/j.clml.2025.08.020}
}
Kostenlos starten →